New Blood Interactive, LLC – Trademark Portfolio
Entity Type: 16
New Blood Interactive, LLC holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 7 filings in this category. The portfolio also extends into Class 16 (Paper Goods) across 2 Nice Classification classes. Currently, 4 trademarks are registered and 1 is pending. Notable registered marks include DUSK, GLOOMWOOD, ULTRAKILL, and FALLEN ACES. The owner is based in Carlsbad, CA.
1206 Plum Tree Road
Carlsbad, CA 92011
Showing of trademarks Trademarks
Trademark Classifications
New Blood Interactive, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Frequently Asked Questions
How many trademarks does New Blood Interactive, LLC have?
New Blood Interactive, LLC has 7 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 pending, 2 abandoned.
What trademark classes does New Blood Interactive, LLC file in?
New Blood Interactive, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 16 (Paper Goods). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are New Blood Interactive, LLC's most well-known trademarks?
New Blood Interactive, LLC's registered trademark portfolio includes well-known marks such as DUSK, GLOOMWOOD, ULTRAKILL, and FALLEN ACES. These are among 4 currently registered trademarks in the portfolio.
What is New Blood Interactive, LLC's trademark registration success rate?
New Blood Interactive, LLC has a 67% trademark registration rate, with 4 out of 6 resolved applications resulting in successful registration. Currently, 1 application is pending review.